Cogent Biosciences Stock Performance
| COGT Stock | USD 36.19 1.01 2.72% |
Cogent Biosciences has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 3.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cogent Biosciences will likely underperform. Cogent Biosciences right now shows a risk of 3.01%. Please confirm Cogent Biosciences value at risk, and the relationship between the jensen alpha and skewness , to decide if Cogent Biosciences will be following its price patterns.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cogent Biosciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, Cogent Biosciences may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return (1.51) | Five Day Return 1.53 | Year To Date Return 7.08 | Ten Year Return (16.29) | All Time Return (16.29) |
Last Split Factor 1:4 | Dividend Date 2020-11-09 | Last Split Date 2020-11-09 |
1 | Is A Final Flush Coming Heres What The Price Action Is Whispering | 11/26/2025 |
2 | Acquisition by Ferrante Karen Jean of 2513 shares of Cogent Biosciences at 8.02 subject to Rule 16b-3 | 11/28/2025 |
3 | Acquisition by Green John L. of 50000 shares of Cogent Biosciences subject to Rule 16b-3 | 12/17/2025 |
4 | Disposition of 90000 shares by John Robinson of Cogent Biosciences at 38.74 subject to Rule 16b-3 | 12/26/2025 |
5 | Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - Investing News Network | 01/13/2026 |
6 | Why Cogent Biosciences Is Up 10.3 percent After Mapping Bezuclastinibs Multi-Indication NDA Strategy | 01/16/2026 |
7 | A Look At Cogent Biosciences Valuation After FDA Accepts Bezuclastinib NDA Under RTOR Program | 01/21/2026 |
8 | Disposition of 3500000 shares by Fairmount Funds Management Llc of Cogent Biosciences at 36.4 subject to Rule 16b-3 | 01/22/2026 |
9 | Cogent Biosciences Director Sells 127,400,000.00 in Stock | 01/23/2026 |
10 | Cogent BiosciencesAnnounces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors | 01/26/2026 |
11 | Acquisition by Fairmount Funds Management Llc of 2777777 shares of Cogent Biosciences at 9.0 subject to Rule 16b-3 | 01/29/2026 |
12 | Cogent Biosciences Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation | 02/02/2026 |
13 | Is FDA Breakthrough Status And Rapid Review For Bezuclastinib Reshaping The Case For Cogent Biosciences | 02/05/2026 |
14 | Cogent Biosciences, Inc. COGT Shares Bought by Candriam S.C.A. - MarketBeat | 02/11/2026 |
| Begin Period Cash Flow | 53.2 M | |
| Total Cashflows From Investing Activities | 38.3 M |
Cogent Biosciences Relative Risk vs. Return Landscape
If you would invest 3,354 in Cogent Biosciences on November 14, 2025 and sell it today you would earn a total of 265.00 from holding Cogent Biosciences or generate 7.9% return on investment over 90 days. Cogent Biosciences is currently generating 0.169% in daily expected returns and assumes 3.0061% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Cogent, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cogent Biosciences Target Price Odds to finish over Current Price
The tendency of Cogent Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 36.19 | 90 days | 36.19 | about 55.73 |
Based on a normal probability distribution, the odds of Cogent Biosciences to move above the current price in 90 days from now is about 55.73 (This Cogent Biosciences probability density function shows the probability of Cogent Stock to fall within a particular range of prices over 90 days) .
Cogent Biosciences Price Density |
| Price |
Predictive Modules for Cogent Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cogent Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cogent Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cogent Biosciences is not an exception. The market had few large corrections towards the Cogent Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cogent Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cogent Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.75 | |
β | Beta against Dow Jones | 3.31 | |
σ | Overall volatility | 4.51 | |
Ir | Information ratio | 0.13 |
Cogent Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cogent Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cogent Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cogent Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (255.86 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (207.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Cogent Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cogent Biosciences, Inc. COGT Shares Bought by Candriam S.C.A. - MarketBeat |
Cogent Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cogent Stock often depends not only on the future outlook of the current and potential Cogent Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cogent Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 103.9 M | |
| Cash And Short Term Investments | 287.1 M |
Cogent Biosciences Fundamentals Growth
Cogent Stock prices reflect investors' perceptions of the future prospects and financial health of Cogent Biosciences, and Cogent Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cogent Stock performance.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 5.58 B | ||||
| Shares Outstanding | 153.51 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 29.97 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (271.59 M) | ||||
| Net Income | (255.86 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 17.47 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.39 X | ||||
| Cash Flow From Operations | (207.79 M) | ||||
| Earnings Per Share | (2.05) X | ||||
| Market Capitalization | 5.8 B | ||||
| Total Asset | 327.9 M | ||||
| Retained Earnings | (859.48 M) | ||||
| Working Capital | 240.76 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
About Cogent Biosciences Performance
Assessing Cogent Biosciences' fundamental ratios provides investors with valuable insights into Cogent Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cogent Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.90) | (0.94) | |
| Return On Capital Employed | (1.17) | (1.22) | |
| Return On Assets | (0.90) | (0.94) | |
| Return On Equity | (1.15) | (1.21) |
Things to note about Cogent Biosciences performance evaluation
Checking the ongoing alerts about Cogent Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cogent Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cogent Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (255.86 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (207.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Cogent Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cogent Biosciences, Inc. COGT Shares Bought by Candriam S.C.A. - MarketBeat |
- Analyzing Cogent Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cogent Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cogent Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cogent Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cogent Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cogent Biosciences' stock. These opinions can provide insight into Cogent Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.